MONTE ROSA THERAPEUTICS INC. - COMMON STOCK

6.7900

18-February-25 12:29:08

15 minutes delayed

Stocks

+0.0100

+0.15%

Today's range

6.7801 - 7.2200

ISIN

N/A

Source

NASDAQ

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

17 Apr 2023 16:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

23 Mar 2023 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

16 Mar 2023 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

03 Feb 2023 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

09 Jan 2023 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:30:01 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

10 Nov 2022 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

01 Nov 2022 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

31 Oct 2022 16:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

20 Oct 2022 16:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader

06 Sep 2022 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

11 Aug 2022 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

11 May 2022 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022

08 Apr 2022 13:00:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

29 Mar 2022 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

03 Feb 2022 16:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

25 Jan 2022 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 07:30:00 By Nasdaq GlobeNewswire
Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

02 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.